| P&L Statement | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 260 | 195 | 374 | 312 |
| Cost of Material Consumed | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 |
| Gross Margins | 100 | 100 | 100 | 100 |
| Employee Benefit Expenses | 34 | 36 | 39 | 43 |
| Other Expenses | 15 | 17 | 93 | 160 |
| EBITDA | 211 | 142 | 242 | 109 |
| OPM | 81.15 | 72.82 | 64.71 | 34.94 |
| Other Income | 44 | 50 | 62 | 66 |
| Finance Cost | 0 | 0 | 0 | 0 |
| D&A | 17 | 19 | 23 | 23 |
| EBIT | 194 | 123 | 219 | 86 |
| EBIT Margins | 74.62 | 63.08 | 58.56 | 27.56 |
| PBT | 238 | 173 | 281 | 152 |
| PBT Margins | 91.54 | 88.72 | 75.13 | 48.72 |
| Tax | 38 | 42 | 84 | 33 |
| PAT | 200 | 331 | 197 | 119 |
| NPM | 76.92 | 67.18 | 52.67 | 38.14 |
| EPS | 2.74 | 1.79 | 2.69 | 1.63 |
| Financial Ratios | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Operating Profit Margin | 81.15 | 72.82 | 64.71 | 34.94 |
| Net Profit Margin | 76.92 | 67.18 | 52.67 | 38.14 |
| Earning Per Share (Diluted) | 2.74 | 1.79 | 2.69 | 1.63 |
| Assets | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Fixed Assets | 229 | 237 | 321 | 310 |
| CWIP | 0 | 0 | 0 | 0 |
| Investments | 2151 | 1966 | 2663 | 2978 |
| Trade Receivables | 16 | 1 | 20 | 3 |
| Inventory | 0 | 0 | 0 | 0 |
| Other Assets | 632 | 922 | 730 | 800 |
| Total Assets | 3028 | 3126 | 3734 | 4091 |
| Liabilities | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Share Capital | 731 | 731 | 731 | 731 |
| FV | 10 | 10 | 10 | 10 |
| Reserves | 2224 | 2343 | 2870 | 3202 |
| Borrowings | 0 | 0 | 0 | 0 |
| Trade Payables | 0 | 0 | 0 | 0 |
| Other Liabilities | 53 | 52 | 133 | 158 |
| Total Liabilities | 3028 | 3126 | 3734 | 4051 |
| Cash-Flow Statement | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| PBT | 237 | 173 | 281 | 152 |
| OPBWC | 74 | 77 | 80 | 82 |
| Change in Receivables | -16 | 15 | -19 | 17 |
| Change in Inventories | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 0 |
| Other Changes | -236 | 0 | -210 | -1 |
| Working Capital Change | -252 | 15 | -229 | 16 |
| Cash Generated From Operations | -178 | 92 | -149 | 98 |
| Tax | -38 | -44 | -41 | -46 |
| Cash Flow From Operations | -216 | 48 | -190 | 52 |
| Purchase of PPE | -1.6 | -27 | -108 | -12 |
| Sale of PPE | 0.5 | 0 | 2 | 0 |
| Cash Flow From Investment | 54 | 243 | -136 | 90 |
| Borrowing | 0 | 0 | 0 | 0 |
| Dividend | 0 | 0 | 0 | 0 |
| Equity | 0 | 0 | 0 | 0 |
| Others From Financing | 0 | 0 | 0 | 0 |
| Cash Flow from Financing | 0 | 0 | 0 | 0 |
| Net Cash Generated | -162 | 291 | -326 | 142 |
| Cash at the Start | 243 | 80 | 371 | 45 |
| Cash at the End | 81 | 371 | 45 | 187 |
Sigachi Laboratories Limited is a prominent name in the pharmaceutical and healthcare sector, known for its commitment to the development, manufacturing, and supply of high-quality active pharmaceutical ingredients (APIs) and intermediates. Over the years, the company has built a strong presence through its emphasis on innovation, regulatory compliance, and adherence to global quality standards. With a robust production infrastructure and a focus on research-driven processes, Sigachi Laboratories has positioned itself as a reliable partner for both domestic and international pharmaceutical companies. Its dedication to operational excellence continues to enhance its credibility in the highly competitive pharma ecosystem.
The unlisted shares of Sigachi Laboratories Limited have garnered growing attention from investors seeking early exposure to companies with strong fundamentals and promising future potential. As an unlisted entity, its shares are traded in the off-market segment, typically attracting long-term investors who recognize the value inherent in pharmaceutical companies with established capabilities. Sigachi Laboratories' consistent performance, expanding product portfolio, and adherence to stringent quality protocols contribute to the perceived value of its unlisted shares. Moreover, the increasing global demand for APIs and the expanding pharmaceutical supply chain further strengthen investor interest.
Investing in Sigachi Laboratories Limited unlisted shares offers an opportunity for portfolio diversification, especially for those looking to participate in the growth of India’s rapidly evolving pharmaceutical sector. However, like all unlisted securities, these shares come with considerations related to liquidity, regulatory compliance, and market volatility. Potential investors must evaluate the company’s financial health, future expansion strategies, and competitive position before making investment decisions. With the pharma sector poised for sustained growth and continuous innovation, Sigachi Laboratories Limited stands out as a company with long-term potential. Nevertheless, conducting thorough due diligence and seeking expert guidance remains essential for maximizing returns and making informed investment choices.
Q:1 How do I confirm the booking of Sigachi Laboratories Limited Unlisted Shares?
Answer: You can confirm the booking by contacting us and agreeing on a trading price for the shares.
Q:2 What documents do I need to provide to buy Sigachi Laboratories Limited Unlisted Shares?Answer: You need to provide your client master report, PAN card, and a cancelled cheque if you are not transferring funds from the bank account mentioned in the CMR copy.These documents are required as per SEBI regulations.
Q:3 What is a client master report and how can I obtain one?Answer: A client master report is a document that provides details about your trading account.You can ask your broker for this document if you do not already have it.
Q:4 How do I make the payment for the shares?Answer: You will be provided with our bank details, and you need to transfer the funds via RTGS, NEFT, IMPS, or cheque transfer.Please note that cash deposits are not accepted.
Q:5 Can I use cash to pay for the shares?
Answer: No, cash deposits are not allowed.Payment must be made through RTGS, NEFT, IMPS, or cheque transfer.
Q:6 What happens after I transfer the funds for the shares?Answer: After you transfer the funds, we will process your order and provide you with confirmation once the shares are successfully allocated to you.
Q:7 Is it necessary to provide a cancelled cheque when purchasing shares?Answer: Yes, a cancelled cheque is required if you are not transferring funds from the bank account as mentioned in your client master report.
Q:8 Are there any specific regulations I need to be aware of when buying unlisted shares?Answer: Yes, you need to follow the KYC regulations as mandated by SEBI, which includes providing necessary identification and account documents.